IMA Wealth Inc. Sells 4,256 Shares of Evolent Health, Inc. (NYSE:EVH)

IMA Wealth Inc. reduced its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 9.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 39,346 shares of the technology company’s stock after selling 4,256 shares during the period. IMA Wealth Inc.’s holdings in Evolent Health were worth $1,300,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Signaturefd LLC raised its position in Evolent Health by 1,470.7% in the 4th quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock worth $48,000 after purchasing an additional 1,353 shares during the period. Nisa Investment Advisors LLC raised its position in Evolent Health by 389.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock worth $137,000 after purchasing an additional 4,006 shares during the period. Strs Ohio raised its position in Evolent Health by 46.3% in the 4th quarter. Strs Ohio now owns 6,000 shares of the technology company’s stock worth $198,000 after purchasing an additional 1,900 shares during the period. Xponance Inc. purchased a new position in Evolent Health in the 4th quarter worth $222,000. Finally, Teacher Retirement System of Texas raised its position in Evolent Health by 9.0% in the 3rd quarter. Teacher Retirement System of Texas now owns 8,293 shares of the technology company’s stock worth $226,000 after purchasing an additional 685 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Canaccord Genuity Group decreased their price objective on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, March 28th. Barclays began coverage on shares of Evolent Health in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $39.00 target price on the stock. JMP Securities lifted their target price on shares of Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research note on Friday, February 23rd. William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research note on Tuesday, January 9th. Finally, Citigroup began coverage on shares of Evolent Health in a research note on Monday, April 22nd. They set a “buy” rating and a $40.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.70.

Evolent Health Stock Down 2.4 %

NYSE:EVH traded down $0.67 during mid-day trading on Friday, hitting $27.65. 1,055,481 shares of the company’s stock were exchanged, compared to its average volume of 764,116. Evolent Health, Inc. has a one year low of $23.33 and a one year high of $36.70. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. The business has a fifty day moving average price of $31.84 and a 200 day moving average price of $30.27. The company has a market cap of $3.19 billion, a PE ratio of -21.77 and a beta of 1.53.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.02 by $0.13. The business had revenue of $556.06 million for the quarter, compared to analyst estimates of $541.87 million. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. Equities analysts predict that Evolent Health, Inc. will post 0.87 EPS for the current year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.